Suven Life Sciences Limited has informed the Exchange regarding a press release dated Jun 16, 2026, titled "Suven Life Sciences announces successful completion and topline results of First-in-Human (FIH) Phase-1 clinical study of SUVN-I6107, a Muscarinic M1 Positive Allosteric Modulator (M1-PAM) and its advancement into Phase-2 clinical development".
Suven Life Sciences Limited Press Release Jun 16 2026
Earlier from Suven Life Sciences
- Suven Life Sciences Limited Press Release Jun 12 2026
- Suven Life Sciences: June 04, 2026Suven Life Sciences Reports Positive DSMB Safety Review and Interim Analysis from Ongoing Global Pha
- Press Release Jun 04 2026
- Press Release May 12 2026